ASweetLife Team, Author at ASweetLife

Lack of Diabetes Supplies in Japan: An Exclusive Report from Noriko Kitano

The number of diabetics in Japan is estimated at over eight million, with millions more suffering from impaired glucose tolerance, or prediabetes. The Japan Diabetes Society says that after last week's devastating earthquake and tsunami in north-east Japan, there are 400-500 survivors with type 1 diabetes in the stricken area...

NYU and Pluristem Partner in Study of Cell-Based Treatment for Diabetic Foot Ulcers

Pluristem Therapeutics, Inc., an Israeli based company developing placenta-based cell therapies, and New York University (NYU) Medical Center today announced the formation of a partnership to study the use of Pluristem’s proprietary placenta-derived PLX cells for the treatment of diabetic foot ulcers...

Victoza Approved for Treatment of Type 2 Diabetes in China

The Chinese State Food and Drug Administration (SFDA) has approved Victoza for the treatment of type 2 diabetes. Diabetes is a rapidly growing disease in China, and Victoza offers a unique treatment option by effectively reducing HbA1c and weight with a low risk of hypoglycemia in people with type 2 diabetes inadequately controlled by oral anti-diabetic agents...

JDRF Announces Children’s Congress 2011

Approximately 150 children and teenagers throughout the U.S., and several from around the world have been selected to travel to Washington, D.C. this summer to represent their state and country and remind Congress and the Administration of the critical need to find better treatments...

Biodel to Accelerate Development of Ultra-Rapid-Acting Insulins

Biodel Inc. has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed...

Raising Funds for Diabetes Research: Do You Have Something to Donate?

Help ASweetLife.org raise funds for diabetes research! We're collecting items and services to auction in Brenda Novak's upcoming Seventh Annual Online Auction to Benefit Diabetes Research. Brenda, mother of five and best-selling author, noticed her youngest son Thad was showing symptoms of diabetes when he was only five-years-old. Soon thereafter he was diagnosed with type 1 diabetes. Learning how to give her son the best possible care wasn’t enough for Brenda, and so she decided to fight diabetes by...

GSK Type 1 Diabetes Drug, Otelixizumab, Fails in Phase 3 Study

GlaxoSmithKline and Tolerx, Inc's Investigatinal immunotherapy, Otelixizumab, for type 1 diabetes failed to meet primary end point in the Phase 3 DEFEND-1 study. Otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide...

Positive Results for Once Monthly Type 2 Diabetes Drug

Positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes were announced by Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. Exenatide once monthly is a new...

Just Peanuts

Many of your supermarket brand name peanut butters are not as good for you as they could be. While peanut butter is an excellent low-carb food, if you choose the wrong kind, you'll find yourself consuming a lot of added sugar and hydrogenated oil. Look around your local supermarket for a moment and you should notice, often on the same shelf, several choices of natural peanut butter.

Type 2 Diabetes Drug, ONGLYZA, Approved for Treatment of Renal Impairment by EU

The European Commission approved a label update for ONGLYZA® (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment following results of a new study submitted by AstraZeneca and Bristol-Myers Squibb Company. The approved dosage for the patient group is a new once-daily 2.5 mg dose...